Payment overview · 2025
General Payments
$995.35
49 reported records · 14 companies
Healthcare provider profile · identity verified
Francis X Walsh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COS COB, CT · NPI 1124174347
Verified facts
What the public records show
CMS Open Payments records show Francis X Walsh, M.D. received $995.35 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Paxlovid, Synthroid, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 731 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $182.14 | 18.3% | 10 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $181.27 | 18.2% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.19 | 16.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.50 | 7.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.90 | 6.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.38 | 5.5% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $48.40 | 4.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.51 | 4.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.60 | 4.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.49 | 4.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.66 | 2.8% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $23.89 | 2.4% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $21.55 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.87 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $995.35 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $181.27 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $155.20 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.81 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.24 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.48 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.48 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.38 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $48.40 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.38 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $47.51 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $47.51 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.67 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $46.67 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $3.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 90 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 30 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 60 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
731 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 1665 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1642 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 1295 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1283 | 116 |
| Losartan Potassium | Losartan Potassium | 1110 | 107 |
| Escitalopram Oxalate | Escitalopram Oxalate | 1044 | 81 |
| Furosemide | Furosemide | 880 | 99 |
| Gabapentin | Gabapentin | 869 | 63 |
| Mirtazapine | Mirtazapine | 778 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 774 | 32 |
| Eliquis | Apixaban | 731 | 52 |
| Sertraline Hcl | Sertraline Hcl | 713 | 32 |
| Lisinopril | Lisinopril | 637 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 533 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 521 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 514 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 452 | 56 |
| Carvedilol | Carvedilol | 426 | 29 |
| Metformin Hcl | Metformin Hcl | 334 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 45 |
| Simvastatin | Simvastatin | 296 | 37 |
| Atenolol | Atenolol | 288 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 282 | 26 |
| Omeprazole | Omeprazole | 274 | 50 |
| Olanzapine | Olanzapine | 264 | suppressed |
| Lorazepam | Lorazepam | 261 | 52 |
| Donepezil Hcl | Donepezil Hcl | 257 | 23 |
| Montelukast Sodium | Montelukast Sodium | 229 | 13 |
| Famotidine | Famotidine | 225 | 17 |
| Memantine Hcl | Memantine Hcl | 218 | 12 |
| Potassium Chloride | Potassium Chloride | 216 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 208 | 19 |
| Azithromycin | Azithromycin | 199 | 141 |
| Lamotrigine | Lamotrigine | 198 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 198 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 22 |
| Finasteride | Finasteride | 196 | 21 |
| Buspirone Hcl | Buspirone Hcl | 192 | 11 |
| Meloxicam | Meloxicam | 185 | 56 |
| Allopurinol | Allopurinol | 180 | 30 |
| Levetiracetam | Levetiracetam | 179 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 171 | 13 |
| Divalproex Sodium | Divalproex Sodium | 170 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 166 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 138 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 137 | 100 |
| Folic Acid | Folic Acid | 135 | suppressed |
| Risperidone | Risperidone | 124 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 117 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 111 | 32 |
| Myrbetriq | Mirabegron | 109 | 12 |
| Alprazolam | Alprazolam | 107 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | suppressed |
| Baclofen | Baclofen | 106 | suppressed |
| Glipizide | Glipizide | 105 | suppressed |
| Ozempic | Semaglutide | 105 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 103 | 20 |
| Xarelto | Rivaroxaban | 102 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 98 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | suppressed |
| Spironolactone | Spironolactone | 96 | 14 |
| Warfarin Sodium | Warfarin Sodium | 95 | 17 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 94 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 90 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 84 | suppressed |
| Januvia | Sitagliptin Phosphate | 84 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 83 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 83 | suppressed |
| Aripiprazole | Aripiprazole | 79 | suppressed |
| Tradjenta | Linagliptin | 79 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 78 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 76 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 76 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 72 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 11 |
| Jardiance | Empagliflozin | 70 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | suppressed |
| Bupropion Xl | Bupropion Hcl | 68 | suppressed |
| Celecoxib | Celecoxib | 67 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | suppressed |
| Fenofibrate | Fenofibrate | 64 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | suppressed |
| Latanoprost | Latanoprost | 63 | 12 |
| Loperamide | Loperamide Hcl | 62 | suppressed |
| Perphenazine | Perphenazine | 62 | suppressed |
| Amoxicillin | Amoxicillin | 61 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 22 |
| Synthroid | Levothyroxine Sodium | 60 | 16 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Topiramate | Topiramate | 55 | suppressed |
| Hydrocortisone | Hydrocortisone | 54 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 54 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 27 |
| Prednisone | Prednisone | 52 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 21 |
| Cephalexin | Cephalexin | 49 | 37 |
| Diazepam | Diazepam | 49 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Lovastatin | Lovastatin | 48 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | suppressed |
| Methylprednisolone | Methylprednisolone | 45 | 32 |
| Sucralfate | Sucralfate | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 41 | suppressed |
| Vascepa | Icosapent Ethyl | 40 | suppressed |
| Clarithromycin | Clarithromycin | 38 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Entacapone | Entacapone | 37 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Gemtesa | Vibegron | 36 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 16 |
| Linzess | Linaclotide | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 14 |
| Mupirocin | Mupirocin | 33 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 29 |
| Paroxetine Er | Paroxetine Hcl | 29 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Salagen | Pilocarpine Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | 12 |
| Cyclosporine | Cyclosporine | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 16 |
| Haloperidol | Haloperidol | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | 16 |
| Valacyclovir | Valacyclovir Hcl | 19 | 14 |
| Anastrozole | Anastrozole | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 15 |
| Dutasteride | Dutasteride | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Telmisartan | Telmisartan | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $995.35 · 49 records | ABBVIE INC. | ABRYSVO, AREXVY, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, GLYCATE, Kerendia, NUPLAZID, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, Rybelsus, SHINGRIX, SYNTHROID, UBRELVY, VRAYLAR, VUMERITY, Wegovy, XIFAXAN, Xhance, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error